{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:44:06Z","timestamp":1778539446126,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,8,20]]},"abstract":"<jats:p>Activation of cell-cycle machinery in Alzheimer\u2019s disease (AD) brain was reported by Mark Smith and colleagues and by other researchers. Among other biochemical processes underlying this activation, the notion that AD brain, under the onslaught of oxidative and nitrosative damage leading to neuronal loss, neurons would attempt to replenish their numbers by entering the cell cycle. However, being post-mitotic, neurons entering the cell cycle would become trapped therein, ultimately leading to death of these neurons. Yang and co-workers and the Butterfield laboratory first reported that similar activation of the cell cycle was present in the brains of individuals with amnestic mild cognitive impairment (MCI), arguably the earliest clinical stage of AD, but who demonstrate normal activities of daily living and no dementia. Activation of the cell cycle in MCI brain is consonant with the concept that this process is an early aspect in the progression of AD. This brief review article discusses these findings and recognizes the contribution of Dr. Mark Smith to the investigation of cell-cycle activation in AD brain and other aspects of AD neuropathology.<\/jats:p>","DOI":"10.3233\/jad-240615","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T11:51:35Z","timestamp":1721389895000},"page":"S277-S281","source":"Crossref","is-referenced-by-count":1,"title":["Activation of the Neuronal Cell Cycle in Brains in Amnestic Mild Cognitive Impairment: Early Involvement in the Progression of Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"100","author":[{"given":"D. Allan","family":"Butterfield","sequence":"first","affiliation":[{"name":"Department of Chemistry and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-240615_ref1","doi-asserted-by":"crossref","unstructured":"Petersen RC . Mild Cognitive Impairment, Aging to Alzheimer\u2019s Disease. Oxford: University Press, 2003.","DOI":"10.1093\/oso\/9780195123425.001.0001"},{"key":"10.3233\/JAD-240615_ref2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1152\/physrev.00030.2022","article-title":"Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease","volume":"104","author":"Perluigi","year":"2024","journal-title":"Physiol Rev"},{"key":"10.3233\/JAD-240615_ref3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","article-title":"Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease","volume":"20","author":"Butterfield","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-240615_ref4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jnc.14589","article-title":"Redox proteomics and amyloid beta-peptide: insights into Alzheimer disease","volume":"151","author":"Butterfield","year":"2019","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-240615_ref5","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1089\/ars.2011.4109","article-title":"Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications","volume":"17","author":"Butterfield","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"10.3233\/JAD-240615_ref6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1471-4159.2001.00451.x","article-title":"The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer\u2019s disease brain: the role of Abeta1-42","volume":"78","author":"Lauderback","year":"2001","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-240615_ref7","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0891-5849(02)00794-3","article-title":"Lipid peroxidation and protein oxidation in Alzheimer\u2019s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress","volume":"32","author":"Butterfield","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"10.3233\/JAD-240615_ref8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.neuropharm.2010.04.005","article-title":"Oxidative stress in Alzheimer disease: a possibility for prevention","volume":"59","author":"Bonda","year":"2010","journal-title":"J Neuropharm"},{"key":"10.3233\/JAD-240615_ref9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/JAD-2002-4316","article-title":"Cell cycle proteins in Alzheimer\u2019s disease: plenty of wheels but no cycle","volume":"4","author":"Bowser","year":"2002","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240615_ref10","first-page":"1933","article-title":"Abnormal expression of the cell cycle regulators P16 CDK4 in Alzheimer\u2019s disease","volume":"150","author":"McShea","year":"1997","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-240615_ref11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1474-9728.2003.00042.x","article-title":"Increased p27, an essential component of cell cycle control, in Alzheimer\u2019s disease","volume":"2","author":"Ogawa","year":"2003","journal-title":"Aging Cell"},{"key":"10.3233\/JAD-240615_ref12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jnen\/59.10.880","article-title":"Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease","volume":"59","author":"Zhu","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-240615_ref13","first-page":"731","article-title":"The cell division cycle and the pathophysiology of Alzheimer\u2019s disease","volume":"87","author":"Nagy","year":"1998","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-240615_ref14","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1097\/00001756-199611250-00050","article-title":"Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer\u2019s disease","volume":"7","author":"Arendt","year":"1996","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-240615_ref15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s004010050665","article-title":"Cell cycle markers in the hippocampus in Alzheimer\u2019s disease","volume":"94","author":"Nagy","year":"1997","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.3233\/JAD-240615_ref16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-7091-6139-5_8","article-title":"Dysregulation of neuronal differentiation and cell cycle control in Alzheimer\u2019s disease","volume":"66","author":"Arendt","year":"2002","journal-title":"J Neural Transm (Suppl)"},{"key":"10.3233\/JAD-240615_ref17","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1523\/JNEUROSCI.23-07-02557.2003","article-title":"Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer\u2019s disease","volume":"23","author":"Yang","year":"2003","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240615_ref18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11064-006-9123-x","article-title":"Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cognitive impairment","volume":"32","author":"Sultana","year":"2007","journal-title":"Neurochem Res"},{"key":"10.3233\/JAD-240615_ref19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12640-011-9287-2","article-title":"Cell cycle proteins in brain in mild cognitive impairment: insights into the progression to Alzheimer disease","volume":"22","author":"Keeney","year":"2012","journal-title":"Neurotox Res"},{"key":"10.3233\/JAD-240615_ref20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrm2261","article-title":"The prolyl isomerase PIN a pivotal new twist in phosphorylation signalling and disease","volume":"8","author":"Lu","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.3233\/JAD-240615_ref21","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/j.1471-4159.2006.03995.x","article-title":"Pin1 in Alzheimer\u2019s disease","volume":"98","author":"Butterfield","year":"2006","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-240615_ref22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00401-002-0581-1","article-title":"Inverse association of Pin1 and tau accumulation in Alzheimer\u2019s disease hippocampus","volume":"104","author":"Holzer","year":"2002","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.3233\/JAD-240615_ref23","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.neurobiolaging.2005.09.021","article-title":"Redox proteomics identification of oxidized proteins in Alzheimer\u2019s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD","volume":"27","author":"Sultana","year":"2005","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-240615_ref24","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.neurobiolaging.2005.05.005","article-title":"Oxidative modification and down-regulation of Pin1 in Alzheimer\u2019s disease hippocampus: a redox proteomics approach","volume":"27","author":"Sultana","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-240615_ref25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nbd.2005.11.002","article-title":"Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer\u2019s disease","volume":"22","author":"Butterfield","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-240615_ref26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature04543","article-title":"The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production","volume":"440","author":"Pastorino","year":"2006","journal-title":"Nature"},{"key":"10.3233\/JAD-240615_ref27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"key":"10.3233\/JAD-240615_ref28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1523\/JNEUROSCI.1698-16.2016","article-title":"Large soluble oligomers of amyloid \u03b2-protein from Alzheimer brain are less neuroactive than the smaller oligomers to which they dissociate","volume":"37","author":"Yang","year":"2017","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240615_ref29","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/21650","article-title":"The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein","volume":"399","author":"Lu","year":"1999","journal-title":"Nature"},{"key":"10.3233\/JAD-240615_ref30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0197-4580(94)00182-Z","article-title":"Degenerative and protective signaling mechanisms in the neurofibrillary pathology of AD","volume":"16","author":"Mattson","year":"1995","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-240615_ref31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2014.12.027","article-title":"Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer\u2019s disease","volume":"76","author":"Chen","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-240615_ref32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/JAD-2000-2212","article-title":"Vitamin E prevents Alzheimer\u2019s amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production","volume":"2","author":"Yatin","year":"2000","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-240615_ref33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/antiox13050574","article-title":"Protein oxidation in aging and Alzheimer\u2019s disease brain","volume":"13","author":"Sultana","year":"2024","journal-title":"Antioxidants"},{"key":"10.3233\/JAD-240615_ref34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/60.8.759","article-title":"Oxidative damage is the earliest event in Alzheimer disease","volume":"60","author":"Nunomura","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-240615_ref35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/01.jnen.0000228136.58062.bf","article-title":"Involvement of oxidative stress in Alzheimer disease","volume":"65","author":"Nunomura","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-240615_ref36","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1523\/JNEUROSCI.17-08-02653.1997","article-title":"Widespread peroxynitrite-mediated damage in Alzheimer\u2019s disease","volume":"17","author":"Smith","year":"1997","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-240615_ref37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/156720506775697124","article-title":"Amyloid beta: the alternate hypothesis","volume":"3","author":"Lee","year":"2006","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-240615_ref38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.freeradbiomed.2009.10.035","article-title":"In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP","volume":"48","author":"Butterfield","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"10.3233\/JAD-240615_ref39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-240615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:58:46Z","timestamp":1777370326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-240615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":39,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-240615","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}